EGCG-Derivative G28 Shows High Efficacy Inhibiting the Mammosphere-Forming Capacity of Sensitive and Resistant TNBC Models

Recent studies showed that Fatty Acid Synthase (FASN), a lipogenic enzyme overexpressed in several carcinomas, plays an important role in drug resistance. Furthermore, the enrichment of Breast Cancer Stem Cell (BCSC) features has been found in breast tumors that progressed after chemotherapy. Hence, we used the triple negative breast cancer (TNBC) cell line MDA-MB-231 (231) to evaluate the FASN and BCSC population role in resistance acquisition to chemotherapy. For this reason, parental cell line (231) and its derivatives resistant to doxorubicin (231DXR) and paclitaxel (231PTR) were used. The Mammosphere-Forming Assay and aldehyde dehydrogenase (ALDH) enzyme activity assay showed an increase in BCSCs in the doxorubicin-resistant model. Moreover, the expression of some transcription factors involved in epithelial-mesenchymal transition (EMT), a process that confers BCSC characteristics, was upregulated after chemotherapy treatment. FASN inhibitors C75, (-)-Epigallocatechin 3-gallate (EGCG), and its synthetic derivatives G28, G56 and G37 were used to evaluate the effect of FASN inhibition on the BCSC-enriched population in our cell lines. G28 showed a noticeable antiproliferative effect in adherent conditions and, interestingly, a high mammosphere-forming inhibition capacity in all cell models. Our preliminary results highlight the importance of studying FASN inhibitors for the treatment of TNBC patients, especially those who progress after chemotherapy.

[1]  D M Parkin,et al.  Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods , 2018, International journal of cancer.

[2]  T. Puig,et al.  Targeting Breast Cancer Stem Cells to Overcome Treatment Resistance , 2018, Molecules.

[3]  L. Feliu,et al.  (−)-Epigallocatechin 3-Gallate Synthetic Analogues Inhibit Fatty Acid Synthase and Show Anticancer Activity in Triple Negative Breast Cancer , 2018, Molecules.

[4]  Hua Yu,et al.  JAK/STAT3-Regulated Fatty Acid β-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance. , 2018, Cell metabolism.

[5]  H. Fujiki,et al.  Human cancer stem cells are a target for cancer prevention using (−)-epigallocatechin gallate , 2017, Journal of Cancer Research and Clinical Oncology.

[6]  J. Brunet,et al.  Fatty acid synthase expression and its association with clinico-histopathological features in triple-negative breast cancer , 2017, Oncotarget.

[7]  J. Balko,et al.  Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease , 2016, Nature Reviews Clinical Oncology.

[8]  A. Russo,et al.  Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway , 2016, Oncotarget.

[9]  E. Cuyás,et al.  Suppression of endogenous lipogenesis induces reversion of the malignant phenotype and normalized differentiation in breast cancer , 2016, Oncotarget.

[10]  S. Devic,et al.  Warburg Effect - a Consequence or the Cause of Carcinogenesis? , 2016, Journal of Cancer.

[11]  A. Welm,et al.  Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer , 2016, Clinical Cancer Research.

[12]  Linda Koshy Vaidyan,et al.  Inhibition of Fatty Acid Synthase Decreases Expression of Stemness Markers in Glioma Stem Cells , 2016, PloS one.

[13]  R. Weinberg,et al.  Distinct EMT programs control normal mammary stem cells and tumour-initiating cells , 2015, Nature.

[14]  I. Berindan‐Neagoe,et al.  Regulation of stem cells-related signaling pathways in response to doxorubicin treatment in Hs578T triple-negative breast cancer cells , 2015, Molecular and Cellular Biochemistry.

[15]  A. Piotrowska,et al.  Expression of EMT Markers SLUG and TWIST in Breast Cancer. , 2015, Anticancer research.

[16]  R. Brugada,et al.  Dual Fatty Acid Synthase and HER2 Signaling Blockade Shows Marked Antitumor Activity against Breast Cancer Models Resistant to Anti-HER2 Drugs , 2015, PloS one.

[17]  F. Mottaghy,et al.  Fatty acid synthase overexpression: target for therapy and reversal of chemoresistance in ovarian cancer , 2015, Journal of Translational Medicine.

[18]  N. Auersperg,et al.  Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells , 2015, International journal of cancer.

[19]  Mihail I Mitov,et al.  Increased expression of fatty acid synthase provides a survival advantage to colorectal cancer cells via upregulation of cellular respiration , 2015, Oncotarget.

[20]  E. Dalmau,et al.  Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer. , 2014, Breast.

[21]  G. Longmore,et al.  Transient SNAIL1 expression is necessary for metastatic competence in breast cancer. , 2014, Cancer research.

[22]  C. Kuperwasser,et al.  SLUG: Critical regulator of epithelial cell identity in breast development and cancer , 2014, Cell adhesion & migration.

[23]  S. Bhattacharya,et al.  Breast cancer stem cells, EMT and therapeutic targets. , 2014, Biochemical and biophysical research communications.

[24]  C. Cordon-Cardo,et al.  Targeting cancer stem cells to suppress acquired chemotherapy resistance , 2014, Oncogene.

[25]  X. Mo,et al.  Comparison of mammosphere formation from breast cancer cell lines and primary breast tumors. , 2014, Journal of thoracic disease.

[26]  M. Dieci,et al.  Relapsed Triple-Negative Breast Cancer: Challenges and Treatment Strategies , 2013, Drugs.

[27]  Shivendra V. Singh,et al.  Inherent and Acquired Resistance to Paclitaxel in Hepatocellular Carcinoma: Molecular Events Involved , 2013, PloS one.

[28]  Jian-Ting Zhang,et al.  Fatty acid synthase causes drug resistance by inhibiting TNF-α and ceramide production[S] , 2013, Journal of Lipid Research.

[29]  Binlei Liu,et al.  Doxorubicin-enriched, ALDHbr mouse breast cancer stem cells are treatable to oncolytic herpes simplex virus type 1 , 2012, BMC Cancer.

[30]  R. Weinberg,et al.  Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. , 2012, Seminars in cancer biology.

[31]  C. Cordon-Cardo,et al.  Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. , 2012, Cancer cell.

[32]  R. Coletta,et al.  The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas , 2012, British Journal of Cancer.

[33]  R. Clarke,et al.  A Detailed Mammosphere Assay Protocol for the Quantification of Breast Stem Cell Activity , 2012, Journal of Mammary Gland Biology and Neoplasia.

[34]  M. Artola,et al.  New synthetic inhibitors of fatty acid synthase with anticancer activity. , 2012, Journal of medicinal chemistry.

[35]  Carrie L. Griffiths,et al.  Triple Negative Breast Cancer: A Brief Review of its Characteristics and Treatment Options , 2012, Journal of pharmacy practice.

[36]  J. Swinnen,et al.  De novo lipogenesis and membrane remodeling in cancer. , 2012 .

[37]  H. Aguilar,et al.  A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines , 2011, Breast Cancer Research.

[38]  G. Wakabayashi,et al.  Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthase , 2011, Breast Cancer Research and Treatment.

[39]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[40]  Charles M. Perou,et al.  Deconstructing the molecular portraits of breast cancer , 2010, Molecular oncology.

[41]  Y. Glinka,et al.  Breast Cancer Stem-Like Cells Are Inhibited by a Non-Toxic Aryl Hydrocarbon Receptor Agonist , 2010, PloS one.

[42]  Sebastian Munck,et al.  De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. , 2010, Cancer research.

[43]  R. Brugada,et al.  Novel anti‐fatty acid synthase compounds with anti‐cancer activity in HER2+ breast cancer , 2010, Annals of the New York Academy of Sciences.

[44]  Jason I. Herschkowitz,et al.  Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.

[45]  Luzhe Sun,et al.  Doxorubicin in Combination with a Small TGFβ Inhibitor: A Potential Novel Therapy for Metastatic Breast Cancer in Mouse Models , 2010, PloS one.

[46]  Jeffrey M. Rosen,et al.  Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features , 2009, Proceedings of the National Academy of Sciences.

[47]  T. Taguchi,et al.  Association of Breast Cancer Stem Cells Identified by Aldehyde Dehydrogenase 1 Expression with Resistance to Sequential Paclitaxel and Epirubicin-Based Chemotherapy for Breast Cancers , 2009, Clinical Cancer Research.

[48]  L. Carey,et al.  Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. , 2009, Clinical breast cancer.

[49]  J. Brunet,et al.  Green tea catechin inhibits fatty acid synthase without stimulating carnitine palmitoyltransferase-1 or inducing weight loss in experimental animals. , 2008, Anticancer research.

[50]  M. Lisanti,et al.  Co-expression of fatty acid synthase and caveolin-1 in pancreatic ductal adenocarcinoma: Implications for tumor progression and clinical outcome , 2008, Cell cycle.

[51]  A. Puisieux,et al.  Generation of Breast Cancer Stem Cells through Epithelial-Mesenchymal Transition , 2008, PloS one.

[52]  J. Taylor‐Papadimitriou,et al.  Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells , 2008, Breast Cancer Research.

[53]  Qiang Yu,et al.  Saturated Fatty Acids Modulate Cell Response to DNA Damage: Implication for Their Role in Tumorigenesis , 2008, PloS one.

[54]  Teresa Puig,et al.  Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75 , 2008, Breast Cancer Research and Treatment.

[55]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[56]  Yang Liu,et al.  A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproduction , 2008, Molecular Cancer Therapeutics.

[57]  R. Xiang,et al.  Characterization of stem cell-like cancer cells in immune-competent mice. , 2006, Blood.

[58]  Jeffrey W. Smith,et al.  Inhibition of endothelial cell proliferation and angiogenesis by orlistat, a fatty acid synthase inhibitor , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[59]  Ken Saito,et al.  Mechanism of apoptosis induced by the inhibition of fatty acid synthase in breast cancer cells. , 2006, Cancer research.

[60]  R. Dhir,et al.  Fatty acid synthase gene overexpression and copy number gain in prostate adenocarcinoma. , 2006, Human pathology.

[61]  H. Beug,et al.  Molecular requirements for epithelial-mesenchymal transition during tumor progression. , 2005, Current opinion in cell biology.

[62]  Robert D Cardiff,et al.  The transcriptional repressor Snail promotes mammary tumor recurrence. , 2005, Cancer cell.

[63]  J. Menéndez,et al.  Pharmacological and small interference RNA‐mediated inhibition of breast cancer‐associated fatty acid synthase (oncogenic antigen‐519) synergistically enhances Taxol (paclitaxel)‐induced cytotoxicity , 2005, International journal of cancer.

[64]  Michael Dean,et al.  Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.

[65]  J. Thiery.  Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.

[66]  M. Gorospe,et al.  Pharmacological inhibition of fatty acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53. , 2001, Cancer research.

[67]  G. Pasternack,et al.  Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. , 1996, Cancer research.

[68]  S. Wakil,et al.  Fatty acid synthase, a proficient multifunctional enzyme. , 1989, Biochemistry.

[69]  O. Warburg.  [Origin of cancer cells]. , 1956, Oncologia.

[70]  S. Verma,et al.  A review of the value of human epidermal growth factor receptor 2 (HER2)-targeted therapies in breast cancer. , 2018, European journal of cancer.

[71]  M. M. U. Castanhole-Nunes,et al.  Relationship between CD44high/CD133high/CD117high cancer stem cells phenotype and Cetuximab and Paclitaxel treatment response in head and neck cancer cell lines. , 2018, American journal of cancer research.

[72]  Jian-Ting Zhang,et al.  Molecular mechanisms of fatty acid synthase (FASN)-mediated resistance to anti-cancer treatments. , 2014, Advances in biological regulation.

[73]  R. Weinberg,et al.  Cell plasticity and heterogeneity in cancer. , 2013, Clinical chemistry.

[74]  Di Chen,et al.  EGCG, green tea polyphenols and their synthetic analogs and prodrugs for human cancer prevention and treatment. , 2011, Advances in clinical chemistry.

[75]  R. Colomer,et al.  [Fatty acid synthase: a new anti-tumor target]. , 2009, Medicina clinica.

[76]  L. Carey,et al.  Metastatic Patterns , and Treatment of Patients with Triple-Negative Breast Cancer , 2009 .